These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10566066)

  • 1. Gp IIb/IIIa antagonists. Summary and table.
    Coleman SG; Duff R
    Drugs R D; 1999 May; 1(5):371-3. PubMed ID: 10566066
    [No Abstract]   [Full Text] [Related]  

  • 2. GP IIb/IIIa antagonists. Clinical experience and potential uses in cardiology.
    Kleiman NS
    Drugs R D; 1999 May; 1(5):361-70. PubMed ID: 10566065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [GP IIb/IIIa receptor antagonists--molecular and clinical aspects].
    Francuz T
    Postepy Hig Med Dosw; 2001; 55(3):419-32. PubMed ID: 11505641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.
    Mak KH; Effron MB; Moliterno DJ
    Drugs Aging; 2000 Mar; 16(3):179-87. PubMed ID: 10803858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of platelet glycoprotein IIb/IIIa receptor inhibitors on outcomes of diabetic patients undergoing percutaneous coronary interventions using sirolimus-eluting stents.
    Nikolsky E; Holmes DR; Mehran R; Dangas G; Schampaert E; Morice MC; Schofer J; Sousa JE; Fahy M; Na Y; Donohoe DJ; Moses JW; Leon MB
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):896-906. PubMed ID: 18498145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy.
    Berger JS; Slater JN; Sherman W; Green SJ; Sanborn TA; Brown DL
    J Thromb Thrombolysis; 2005 Feb; 19(1):47-54. PubMed ID: 15976967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.
    Leebeek FW; Boersma E; Cannon CP; van de Werf FJ; Simoons ML
    Eur Heart J; 2002 Mar; 23(6):444-57. PubMed ID: 11863347
    [No Abstract]   [Full Text] [Related]  

  • 8. FK 633. FR 144633.
    Drugs R D; 1999 May; 1(5):375-6. PubMed ID: 10566067
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
    Sebastian M; Makkar R
    Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa inhibitors.
    Rosove MH
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):65-76. PubMed ID: 15171958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
    Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
    J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies surrounding platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention and acute coronary syndromes.
    Harrington RA
    Semin Thromb Hemost; 2004 Dec; 30(6):639-47. PubMed ID: 15630670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents.
    Schafer AI
    Tex Heart Inst J; 1997; 24(2):90-6. PubMed ID: 9205981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.
    Aalto-Setälä K; Karhunen PJ; Mikkelsson J; Niemelä K
    J Thromb Thrombolysis; 2005 Aug; 20(1):57-63. PubMed ID: 16133898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
    Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
    Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
    Ahrens I; Peter K; Bode C
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF; Miller MW; Thompson CA; Dale GL
    J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.